Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome
Identifieur interne : 003682 ( Main/Exploration ); précédent : 003681; suivant : 003683Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome
Auteurs : Yasser Awaad [États-Unis] ; Anne Marie Michon [États-Unis] ; Sarah Minarik [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2005-06.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Enfant.
English descriptors
- KwdEn :
- Adolescent, Anticonvulsants (therapeutic use), Child, Demography, Dose-Response Relationship, Drug, Educational Status, Female, Gilles de la Tourette syndrome, Humans, Levetiracetam, Male, Nervous system diseases, Piracetam (analogs & derivatives), Piracetam (therapeutic use), Prospective Studies, Psychiatric Status Rating Scales, Severity of Illness Index, Tic, Tics (drug therapy), Tics (etiology), Tourette Syndrome (complications), Tourette syndrome, Treatment, Treatment Outcome, levetiracetam, tics.
- MESH :
- chemical , analogs & derivatives : Piracetam.
- chemical , therapeutic use : Anticonvulsants, Piracetam.
- complications : Tourette Syndrome.
- drug therapy : Tics.
- etiology : Tics.
- Adolescent, Child, Demography, Dose-Response Relationship, Drug, Educational Status, Female, Humans, Male, Prospective Studies, Psychiatric Status Rating Scales, Severity of Illness Index, Treatment Outcome.
Abstract
Some drugs currently used to treat tics in pediatric patients have drawbacks, including the risk of side effects. New therapeutic options with better safety profiles are needed. Levetiracetam is an antiepileptic drug with atypical mechanisms of action that might be beneficial for this indication. We evaluated the effects of levetiracetam on motor and vocal tics, behavior, and school performance in children and adolescents with tics and Tourette syndrome (TS). Sixty patients, ≤18 years of age, with tics and TS were enrolled in this prospective, open‐label study. The initial starting dose of levetiracetam was 250 mg/day. The dosage was titrated over 3 weeks to 1,000 to 2,000 mg/day. Clinical outcomes were assessed with the Clinical Global Impression Scale, Yale Global Tic Severity Scale, and Revised Conners' Parent Rating Scale. Behavior and school performance were also recorded. All 60 patients showed improvements based on all of the scales used, and 43 patients improved with regard to behavior and school performance. Levetiracetam was generally well tolerated. Three patients discontinued treatment because of exaggeration of preexisting behavioral problems. Levetiracetam may be useful in treating tics in children and adolescents. Given its established safety profile, levetiracetam is a candidate for evaluation in a well‐controlled trial. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20385
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002896
- to stream Istex, to step Curation: 002896
- to stream Istex, to step Checkpoint: 002088
- to stream PubMed, to step Corpus: 003156
- to stream PubMed, to step Curation: 003156
- to stream PubMed, to step Checkpoint: 002F14
- to stream Ncbi, to step Merge: 001145
- to stream Ncbi, to step Curation: 001145
- to stream Ncbi, to step Checkpoint: 001145
- to stream Main, to step Merge: 004D65
- to stream PascalFrancis, to step Corpus: 001E56
- to stream PascalFrancis, to step Curation: 000E65
- to stream PascalFrancis, to step Checkpoint: 001C72
- to stream Main, to step Merge: 005150
- to stream Main, to step Curation: 003682
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome</title><author><name sortKey="Awaad, Yasser" sort="Awaad, Yasser" uniqKey="Awaad Y" first="Yasser" last="Awaad">Yasser Awaad</name></author><author><name sortKey="Michon, Anne Marie" sort="Michon, Anne Marie" uniqKey="Michon A" first="Anne Marie" last="Michon">Anne Marie Michon</name></author><author><name sortKey="Minarik, Sarah" sort="Minarik, Sarah" uniqKey="Minarik S" first="Sarah" last="Minarik">Sarah Minarik</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7D3B90EC700779A6A345358D9E44E52A9716ACBE</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/mds.20385</idno><idno type="url">https://api.istex.fr/document/7D3B90EC700779A6A345358D9E44E52A9716ACBE/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002896</idno><idno type="wicri:Area/Istex/Curation">002896</idno><idno type="wicri:Area/Istex/Checkpoint">002088</idno><idno type="wicri:doubleKey">0885-3185:2005:Awaad Y:use:of:levetiracetam</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15704204</idno><idno type="wicri:Area/PubMed/Corpus">003156</idno><idno type="wicri:Area/PubMed/Curation">003156</idno><idno type="wicri:Area/PubMed/Checkpoint">002F14</idno><idno type="wicri:Area/Ncbi/Merge">001145</idno><idno type="wicri:Area/Ncbi/Curation">001145</idno><idno type="wicri:Area/Ncbi/Checkpoint">001145</idno><idno type="wicri:doubleKey">0885-3185:2005:Awaad Y:use:of:levetiracetam</idno><idno type="wicri:Area/Main/Merge">004D65</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:05-0363478</idno><idno type="wicri:Area/PascalFrancis/Corpus">001E56</idno><idno type="wicri:Area/PascalFrancis/Curation">000E65</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001C72</idno><idno type="wicri:doubleKey">0885-3185:2005:Awaad Y:use:of:levetiracetam</idno><idno type="wicri:Area/Main/Merge">005150</idno><idno type="wicri:Area/Main/Curation">003682</idno><idno type="wicri:Area/Main/Exploration">003682</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome</title><author><name sortKey="Awaad, Yasser" sort="Awaad, Yasser" uniqKey="Awaad Y" first="Yasser" last="Awaad">Yasser Awaad</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatrics, Oakwood Healthcare System, University of Michigan Medical School, Dearborn, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Michon, Anne Marie" sort="Michon, Anne Marie" uniqKey="Michon A" first="Anne Marie" last="Michon">Anne Marie Michon</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatrics, Oakwood Healthcare System, University of Michigan Medical School, Dearborn, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Minarik, Sarah" sort="Minarik, Sarah" uniqKey="Minarik S" first="Sarah" last="Minarik">Sarah Minarik</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pediatrics, Oakwood Healthcare System, University of Michigan Medical School, Dearborn, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-06">2005-06</date><biblScope unit="vol">20</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="714">714</biblScope><biblScope unit="page" to="718">718</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7D3B90EC700779A6A345358D9E44E52A9716ACBE</idno><idno type="DOI">10.1002/mds.20385</idno><idno type="ArticleID">MDS20385</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Anticonvulsants (therapeutic use)</term><term>Child</term><term>Demography</term><term>Dose-Response Relationship, Drug</term><term>Educational Status</term><term>Female</term><term>Gilles de la Tourette syndrome</term><term>Humans</term><term>Levetiracetam</term><term>Male</term><term>Nervous system diseases</term><term>Piracetam (analogs & derivatives)</term><term>Piracetam (therapeutic use)</term><term>Prospective Studies</term><term>Psychiatric Status Rating Scales</term><term>Severity of Illness Index</term><term>Tic</term><term>Tics (drug therapy)</term><term>Tics (etiology)</term><term>Tourette Syndrome (complications)</term><term>Tourette syndrome</term><term>Treatment</term><term>Treatment Outcome</term><term>levetiracetam</term><term>tics</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Piracetam</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term><term>Piracetam</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Tourette Syndrome</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Tics</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Tics</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Child</term><term>Demography</term><term>Dose-Response Relationship, Drug</term><term>Educational Status</term><term>Female</term><term>Humans</term><term>Male</term><term>Prospective Studies</term><term>Psychiatric Status Rating Scales</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Adolescent</term><term>Enfant</term><term>Gilles de la Tourette syndrome</term><term>Lévétiracétam</term><term>Système nerveux pathologie</term><term>Tic</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Enfant</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Some drugs currently used to treat tics in pediatric patients have drawbacks, including the risk of side effects. New therapeutic options with better safety profiles are needed. Levetiracetam is an antiepileptic drug with atypical mechanisms of action that might be beneficial for this indication. We evaluated the effects of levetiracetam on motor and vocal tics, behavior, and school performance in children and adolescents with tics and Tourette syndrome (TS). Sixty patients, ≤18 years of age, with tics and TS were enrolled in this prospective, open‐label study. The initial starting dose of levetiracetam was 250 mg/day. The dosage was titrated over 3 weeks to 1,000 to 2,000 mg/day. Clinical outcomes were assessed with the Clinical Global Impression Scale, Yale Global Tic Severity Scale, and Revised Conners' Parent Rating Scale. Behavior and school performance were also recorded. All 60 patients showed improvements based on all of the scales used, and 43 patients improved with regard to behavior and school performance. Levetiracetam was generally well tolerated. Three patients discontinued treatment because of exaggeration of preexisting behavioral problems. Levetiracetam may be useful in treating tics in children and adolescents. Given its established safety profile, levetiracetam is a candidate for evaluation in a well‐controlled trial. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Michigan</li></region></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Awaad, Yasser" sort="Awaad, Yasser" uniqKey="Awaad Y" first="Yasser" last="Awaad">Yasser Awaad</name></region><name sortKey="Michon, Anne Marie" sort="Michon, Anne Marie" uniqKey="Michon A" first="Anne Marie" last="Michon">Anne Marie Michon</name><name sortKey="Minarik, Sarah" sort="Minarik, Sarah" uniqKey="Minarik S" first="Sarah" last="Minarik">Sarah Minarik</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003682 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003682 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7D3B90EC700779A6A345358D9E44E52A9716ACBE
|texte= Use of levetiracetam to treat tics in children and adolescents with Tourette syndrome
}}
| This area was generated with Dilib version V0.6.23. |  |